Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2012
  • Online publication date: August 2012

6 - Evidence-based pharmacotherapy of social anxiety disorder

References

Allgulander, CI (1999). Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatrica Scandinavica 100, 196–198.
Allgulander CI, Mangano R, Zhang J et al. (2004). Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology: Clinical and Experimental 9, 387–396.
American Psychiatric Association (APA) (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn) – Text Revision. Washington, DC: American Psychiatric Association.
Amies PL, Gelder MG, Shaw PM (1983). Social phobia: a comparative clinical study. British Journal of Psychiatry 142, 174–179.
Baldwin D, Bobes, J, Stein DJ et al. (1999). Paroxetine in social phobia/social anxiety disorder: randomized, double-blind, placebo-controlled study. British Journal of Psychiatry 175, 120–126.
Barnett SD, Kramer ML, Casat CD et al. (2002). Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology 16, 365–368.
Black B, Uhde TW, Tancer ME (1992). Fluoxetine for the treatment of social phobia. Journal of Clinical Psychopharmacology 12, 293–295.
Blanco C, Heimberg RG, Schneier FR et al. (2010 a). A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry 67, 286–295.
Blanco C, Okuda M, Markowitz JC et al. (2010 b). The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 71, 1645–1656.
Blanco C, Olfson M, Okuda M et al. (2008). Generalizability of clinical trials for alcohol dependence to community samples. Drug and Alcohol Dependence 98, 123–128.
Blanco C, Raza MS, Schneier FR, Liebowitz MR (2003 a). The evidence-based pharmacological treatment of social anxiety disorder. International Journal of Neuropsychopharmacology 6, 427–442.
Blanco C, Schneier FR, Schmidt AB et al. (2003 b). Pharmacological treatment of social anxiety disorder: a meta-analysis. Depression and Anxiety 18, 29–40.
Blomhoff, S, Haug TT, Hellstrom K et al. (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry 179, 23–30.
Clark D, Agras WS (1991). The assessment and treatment of performance anxiety in musicians. American Journal of Psychiatry 148, 598–605.
Clark DM, Ehlers A, McManus F et al. (2003). Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. Journal of Consulting and Clinical Psychology 71, 1058–1067.
Davidson JR, Foa EB, Huppert JD et al. (2004 a). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 61, 1005–1013.
Davidson, JR, Potts N, Richichi E et al. (1993). Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology 13, 423–428.
Davidson JR, Yaryura-Tobias J, DuPont R et al. (2004 b). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 118–125.
Fedoroff IC, Taylor S. (2001). Psychological and pharmacological treatments of social phobia: a meta-analysis. Journal of Clinical Psychopharmacology 21, 311–323.
Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R (2011). Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. International Clinical Psychopharmacology 26(4), 213–220.
Fleiss JL (1994). Measures of effect size for categorical data. In Cooper H, Hedges L (Eds.), The Handbook of Research Synthesis (pp. 245–260). New York, NY: Russell Sage Foundation.
Gelernter CS, Uhde TW, Cimbolic P et al. (1991). Cognitive‑behavioral and pharmacological treatments of social phobia: A controlled study. Archives of General Psychiatry, 48, 938–945.
Glesser, LJ, Olkin I (1994). Stochastically dependent effect sizes. In Cooper H, Hedges L (Eds.), The Handbook of Research Synthesis (pp. 339–356). New York, NY: Russell Sage Foundation.
Gould RA, Buckminister S, Pollack MH et al. (1997). Cognitive-behavioral and pharmacological treatments of social phobia: a meta-analysis. Clinical Psychology: Science and Practice 4, 291–306.
Grant BF, Hasin DS, Blanco C, Stinson FS et al. (2005). The epidemiology of social anxiety disorder in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 66, 1351–1361.
Guastella AJ, Richardson R, Lovibond PF et al. (2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry 63, 544–549.
Hedges DW, Brown BL, Shwalb DA et al. (2007). The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. Journal of Psychopharmacology 21, 102–111.
Hedges LV, Olkin, I (1985). Statistical Methods for Meta-analysis. Orlando, FL: Academic Press.
Heimberg RG, Horner KJ, Juster HR et al. (1999). Psychometric properties of the Liebowitz Social Anxiety Scale. Psychological Medicine 29, 199–212.
Heimberg RG, Liebowitz MR, Hope DA et al. (1998). Cognitive-behavioral group therapy vs phenelzine therapy for social phobia. Archives of General Psychiatry 55, 1133–1141.
Hofmann SG, Meuret AE, Smits JA et al. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry 63, 298–304.
Kasper S, Stein DJ, Loft H, Nil R (2005). Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. British Journal of Psychiatry 186, 222–226.
Katschnig H, Stein MB, Buller R (1997). Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 247, 71–80.
Katzelnick DJ, Kobak KA, Greist JH et al. (1995). Sertraline for social phobia: a double-blind, placebo-controlled cross-over study. American Journal of Psychiatry 152, 1368–1371.
Kobak KA, Griest JH, Jefferson JW, Katzelnick DJ (2002). Fluoxetine in social phobia: a double-blind placebo controlled pilot study. Journal of Clinical Psychopharmacology 22, 257–262.
Lader M, Stender K, Burger V, Nil R (2004). Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety 19, 241–248.
Lepola U, Bergtholdt B, St Lambert J et al. (2004). Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 65, 222–229.
Liebowitz MR (1987). Social phobia. Modern Problems of Pharmacopsychiatry 22, 141–173.
Liebowitz MR, DeMartinis NA, Weihs et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 785–792.
Liebowitz MR, Gelenberg AJ, Munjack D (2005 a). Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 62, 190–198.
Liebowitz MR, Heimberg RG, Schneier FR et al. (1999). Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 10, 89–98.
Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005 b). A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 238–247.
Liebowitz MR, Schneier FR, Campeas R et al. (1992). Phenelzine vs. atenolol in social phobia: a placebo‑controlled comparison. Archives of General Psychiatry 49, 290–300.
Liebowitz MR, Stein MB, Tancer M et al. (2002). A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 63, 66–74.
Marks IM (1970). The classification of phobic disorders. British Journal of Psychiatry 116, 377–386.
Montgomery SA, Nil R, Durr-Pal N et al. (2005). A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Journal of Clinical Psychiatry 66, 1270–1278.
Muehlbacher M, Nickel MK, Nickel C et al. (2005). Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 25, 580–583.
Munjack DJ, Baltazar PL, Bohn PB et al. (1990). Clonazepam in the treatment of social phobia: a pilot study. Journal of Clinical Psychiatry 51 (Suppl.), 35–53.
Noyes R, Moroz G, Davidson J et al. (1997). Moclobemide in social phobia: a controlled dose-response. Journal of Clinical Psychopharmacology 17, 247–254.
Öst LG (1987). Age of onset in different phobias. Journal of Abnormal Psychology 96, 223–229.
Pande AC, Davidson RT, Jefferson JW et al. (1999). Treatment of social phobia with gabapentin: a placebo controlled study. Journal of Clinical Psychopharmacology 19, 341–348.
Potts NLS, Davidson JRT (1995). Pharmacological treatments: literature review. In Heimberg RG, Liebowitz MR,Hope DA, Schneier FR (Eds.), Social Phobia: Diagnosis, Assessment and Treatment (pp. 334–365) New York, NY: Guilford Press.
Rickels K, Mangano R, Khan A (2004). A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 488–496.
Schneier FR, Blanco C, Campeas R et al. (2003). Citalopram treatment of social anxiety disorder and comorbid major depression. Depression and Anxiety 17, 191–196.
Schneier FR, Chin SJ, Hollander E, Liebowitz MR (1992 a). Fluoxetine in social phobia. Journal of Clinical Psychopharmacology 12, 62–64.
Schneier FR, Goetz D, Campeas R et al. (1998). A placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry 172, 70–77.
Schneier FR, Johnson J, Hornig CD et al. (1992 b). Social phobia: comorbidity and morbidity in an epidemiological sample. Archives of General Psychiatry 49, 282–288.
Schneier FR, Saoud JB (1993). Buspirone in social phobia. Journal of Clinical Psychopharmacology 13, 251–256.
Schutters SI, Van Megen HJ, Van Veen JF et al. (2010). Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. International Journal of Clinical Psychopharmacology 25, 302–304.
Seedat S, Stein MB (2004). Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Journal of Clinical Psychiatry 65, 244–248.
Simon NM, Korbly NB, Worthington JJ et al. (2002). Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients. CNS Spectrums 7, 655–657.
Simpson HB, Schneier FR, Campeas RB et al. (1998). Imipramine in the treatment of social phobia. Journal of Clinical Psychopharmacology 18, 132–135.
Stein DJ, Cameron A, Amrein R, Montgomery SA (2002 a). Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology 17, 161–170.
Stein DJ, Stein MB, Pitts CD et al. (2002 b). Predictors of response to pharmacotherapy in social anxiety disorder, an analysis of 3 placebo-controlled paroxetine trials. Journal of Clinical Psychiatry 63, 152–155.
Stein DJ, Versiani M, Hair T, Kumar R (2002 c). Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Archives of General Psychiatry 59, 1111–1118.
Stein MB, Fyer AJ, Davidson JRT et al. (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind placebo-controlled study. American Journal of Psychiatry 156, 756–760.
Stein MB, Liebowitz MR, Lydiard RB et al. (1998). Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized, double-blind, placebo-controlled study. Journal of the American Medical Association 280, 708–713.
Stein MB, Pollack MH, Bystritsky A et al. (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology 177, 280–288.
Stein MB, Sareen J, Hami S, Chao J (2001). Pindolol potentiation of paroxetine for generalized social phobia. A double-blind, placebo-controlled, cross-over study. American Journal of Psychiatry 158, 1725–1727.
Sternbach H (1990). Fluoxetine treatment of social phobia. Journal of Clinical Psychopharmacology 10, 230–231.
Turner SM, Beidel DC, Jacob RG (1994). Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting Clinical Psychology 62, 350–358.
Van Ameringen MA, Lane RM, Walker JR et al. (2001). Sertraline treatment of generalized social phobia: a 20-week double-blind, placebo-controlled study. American Journal of Psychiatry, 158, 275–281.
Van Ameringen M, Mancini C, Oakman J et al. (2007). Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 68, 288–295.
Van Ameringen M, Mancini C, Streiner DL (1993). Fluoxetine efficacy in social phobia. Journal of Clinical Psychiatry 54, 27–32.
Van der Linden GJH, Stein DJ, Van Balkom A (2000). The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder: a meta-analysis of randomized controlled trials. International Clinical Psychopharmacology 15 (Suppl.), S15–S23.
van Vliet IM, den Boer JA, Westenberg HGM (1994). Psychopharmacological treatment of social phobia: a double blind controlled study with fluvoxamine. Psychopharmacology 115, 128–134.
van Vliet IM, den Boer JA, Westenberg HGM, Ho Pian KL (1997) Clinical effects of buspirone in social phobia: a double-blind placebo controlled study. Journal of Clinical Psychiatry 58, 164–168.
Versiani M, Amrein R, Montgomery SA (1997 a). Social phobia: long-term treatment outcome and prediction of response – a moclobemide study. International Clinical Psychopharmacology 12, 239–254.
Versiani M, Nardia AE, Figueira I et al. (1997 b). Double-blind placebo controlled trials with bromazepam. Jornal Brasileiro de Psiquiatria 46, 167–171.
Versiani M, Nardi AE, Mundim FD et al. (1992). Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. British Journal of Psychiatry 161, 353–360.
Wagner KD (2003). Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacology Bulletin 37 (Suppl.), 167–175.
Walker JR, Van Ameringen MA, Swinson R et al. (2000). Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology 20, 636–644.
Westenberg HG, Stein DJ, Yang H et al. (2004). A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 49–55.
Wittchen HU, Beloch E (1996). The impact of social phobia on quality of life. International Clinical Psychopharmacology 11 (Suppl.), 15–23.
Zhang W, Connor KM, Davidson JR (2005). Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology 19, 551–553.
Zitrin CM, Klein DF, Woerner MG, Ross DC (1983). Treatment of phobias: a comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry 40, 125–138.